The eatertainment brand saw same-store sales fall 7.7% last quarter, and failed to maintain a leverage ratio required by a financing covenant.
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report), with a price ...
In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price ...
When we spoke three years ago, your research was focused on the shopping center, net lease and health care subsectors. Is there anything new or different about your coverage universe here in 2025? Mr.
Wall Street is gearing up for another wave of blank check companies from seasoned and first-time sponsors, showing the ...
On Thursday, BTIG analyst Justin Zelin downgraded Kura Oncology stock (NASDAQ:KURA) from Buy to Neutral. Zelin cited concerns over the recent KOMET-001 study results for the company's drug, ziftomenib ...
To schedule a one-on-one meeting, investors are encouraged to contact their BTIG representative. This press release includes forward-looking statements that involve risk and uncertainties.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback